Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Refractory Malignant Neoplasm: early-phase trial registry

A small indexed set (5 trials) with no open enrollment listed right now.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

Browse conditions → How counts are built

5 US clinical trials · none currently recruiting · #3,391 of 28,707 conditions by registered trial count

Refractory Malignant Neoplasm: 5 US clinical trials tracked, none currently recruiting.

Refractory Malignant Neoplasm is the subject of 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 4 of these trials.

Enrollment posture brief

Registry condition refractory-malignant-neoplasm

OPEN 0 | RECR 0% | LATE 0 | EARLY 3 | RANK #3391 | SPON 4

Volume-matched condition peers

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Refractory Malignant Neo (th…0%
Open-enrollment share among volume-matched conditions near Refractory Malignant Neoplasm

Refractory Malignant Neoplasm has no open enrollment in this registry pull (5 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Refractory Malignant Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Refractory Malignant Neoplasm is recruiting below its size-band peers.

    0 of 5 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Refractory Malignant Neoplasm research.

    M.D. Anderson Cancer Center accounts for 4 of 5 trials (80%). 2 distinct sponsors appear on at least one study for this condition label.

  3. Most Refractory Malignant Neoplasm trials plan to enrol fewer than 100 people.

    Median target enrolment is 90 among the 5 trials that report a genuine target (sentinel values excluded). 3 of those (60%) plan for fewer than 100 participants.

  4. Refractory Malignant Neoplasm splits between interventional and observational designs.

    3 interventional and 2 observational studies make up this index (60% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 22

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 2

Top Sponsors

M.D. Anderson Cancer Center 4 trials
University of California, San Francisco 1 trials

Named interventions

Most-linked intervention names on Refractory Malignant Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Questionnaire Administration Other
2 trials
Laboratory Biomarker Analysis Other
2 trials
Quality-of-Life Assessment Other
2 trials
Fluorine F 18-fluoroazomycin Arabinoside Drug
1 trials
Pegylated Liposomal Doxorubicin Hydrochloride Drug
1 trials
Pharmacological Study Other
1 trials
Bevacizumab Biological
1 trials
Exercise Intervention Behavioral
1 trials

US sites by state

Facility locations filed on Refractory Malignant Neoplasm trials. A trial with sites in several states counts in each.

Texas 4 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Refractory Malignant Neoplasm page

5 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Refractory Malignant Neoplasm trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • M.D. Anderson Cancer Center sponsors the most Refractory Malignant Neoplasm trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Refractory Malignant Neoplasm condition card totals 5 registered trials; most-linked intervention Questionnaire Administration; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.